{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:37:02Z","timestamp":1787009822004,"version":"build-2736575974"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Sugammadex is a novel selective muscle relaxant binding agent capable of reversing deep neuromuscular blockade from rocuronium or vecuronium. It has not been approved for use in children by the US FDA because of lack of literature regarding pediatric patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>A series of new studies has reported sugammadex administration to increasingly younger patients ranging in the newborn period. Although the literature in pediatrics is improving, most of the available studies in pediatrics are underpowered, retrospective, and measure too many different variables to draw reliable, collective conclusions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>All available evidence suggests that sugammadex is likely well tolerated and effective and can be dosed similarly to adults in patients 2 years\u2019 old and greater. Sugammadex should be used with caution in patients less than 2 years old.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aco.0000000000000847","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T04:00:46Z","timestamp":1587614446000},"page":"374-380","source":"Crossref","is-referenced-by-count":13,"title":["Sugammadex and neuromuscular reversal: special focus on neonatal and infant populations"],"prefix":"10.1097","volume":"33","author":[{"given":"Eliot","family":"Grigg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230827","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4103\/0259-1162.123211","article-title":"Sugammadex: a revolutionary drug in neuromuscular pharmacology","volume":"7","author":"Nag","year":"2013","journal-title":"Anesth Essays Res"},{"key":"R2-20230827","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jclinane.2009.05.002","article-title":"Sugammadex: the first selective binding reversal agent for neuromuscular block","volume":"21","author":"Kovac","year":"2009","journal-title":"J Clin Anesth"},{"key":"R3-20230827","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/ALN.0000000000001744","article-title":"Reversal of veruconium-induced neuromuscular blockade with low-dose sugammadex at train-of-four count of four: a randomized controlled trial","volume":"127","author":"Asztalos","year":"2017","journal-title":"Anesthesiology"},{"key":"R4-20230827","first-page":"53","article-title":"The development and regulatory history of sugammadex in the United States. Anesthesia Patient Safety Foundation Newsletter","volume":"30","author":"Murphy","year":"2016","journal-title":"Circulation"},{"key":"R5-20230827","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/ALN.0000000000000424","article-title":"Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients","volume":"121","author":"Rahe-Meyer","year":"2014","journal-title":"Anesthesiology"},{"key":"R6-20230827","doi-asserted-by":"crossref","first-page":"595","DOI":"10.5414\/CP201693","article-title":"Sugammadex is not associated with QT\/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study","volume":"50","author":"deKam","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R7-20230827","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40261-013-0095-8","article-title":"Effect of sugammadex on QT\/QTc interval prolongation when combined with QTc-prolonging sevoflurane or propofol anaesthesia","volume":"33","author":"deKam","year":"2013","journal-title":"Clin Drug Investig"},{"key":"R9-20230827","article-title":"Neostigmine versus sugammadex for reversal of neuromuscular blockade and effects on reintubation for respiratory failure or newly initiated noninvasive ventilation: an interrupted time series design","author":"Krause","year":"2019","journal-title":"Anesth Analg"},{"key":"R10-20230827","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1460-9592.2011.03624.x","article-title":"Case report: sugammadex used to successfully reverse vecuronium-induced neuromuscular blockade in a 7-month-old infant","volume":"21","author":"Buchanan","year":"2011","journal-title":"Paediatr Anaesth"},{"key":"R11-20230827","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/pan.13643","article-title":"Case Series of 331 doses of Sugammadex compared to Neostigmine in patients under 2-years-old","volume":"29","author":"Franz","year":"2019","journal-title":"Pediatr Anesth"},{"key":"R12-20230827","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jclinane.2017.06.006","article-title":"Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: a pooled analysis of 26 studies","volume":"41","author":"Herring","year":"2017","journal-title":"J Clin Anesth"},{"key":"R13-20230827","doi-asserted-by":"crossref","first-page":"11268","DOI":"10.1038\/s41598-019-47784-3","article-title":"Effect of protracted dexamethasone exposure and its withdrawal on rocuronium-induced neuromuscular blockade and sugammadex reversal: an ex vivo rat study","volume":"9","author":"Oh","year":"2019","journal-title":"Sci Rep"},{"key":"R14-20230827","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/joacp.JOACP_42_17","article-title":"Is there an interaction between dexamethasone and sugammadex in real clinical conditions? A randomized controlled trial in patients undergoing laparoscopic cholecystectomy","volume":"35","author":"Batistaki","year":"2019","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"R15-20230827","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4097\/kja.d.18.00238","article-title":"Effects of dexamethasone and hydrocortisone on rocuronium-induced neuromuscular blockade and reversal by sugammadex in phrenic nerve-hemidiaphragm rat model","volume":"72","author":"Choi","year":"2019","journal-title":"Korean J Anesthesiol"},{"key":"R16-20230827","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12871-016-0254-6","article-title":"Dexamethasone does not diminish sugammadex reversal of neuromuscular block - clinical study in surgical patients undergoing general anesthesia","volume":"16","author":"Rezonja","year":"2016","journal-title":"BMC Anesthesiol"},{"key":"R17-20230827","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5152\/TJAR.2019.67760","article-title":"Effect of concurrent lidocaine, remifentanil and methylprednisolone use on the clinical effect of sugammadex under general anaesthesia in rats","volume":"47","author":"Kandemir","year":"2019","journal-title":"Turk J Anaesthesiol Reanim"},{"key":"R18-20230827","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00540-019-02681-x","article-title":"Remifentanil does not inhibit sugammadex reversal after rocuronium-induced neuromuscular block in the isolated hemidiaphragm of the rat: an ex vivo study","volume":"33","author":"Choi","year":"2019","journal-title":"J Anesth"},{"key":"R19-20230827","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1213\/XAA.0000000000001058","article-title":"Delayed neuromuscular blockade reversal with sugammadex after vecuronium, desflurane, and magnesium administration: a case report","volume":"13","author":"Brown","year":"2019","journal-title":"A A Pract"},{"key":"R20-20230827","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jclinane.2019.08.048","article-title":"Does the pretreatment of magnesium sulphate affect the sugammadex reversal time for rocuronium-induced neuromuscular blockade? A meta-analysis","volume":"60","author":"Miao","year":"2020","journal-title":"J Clin Anesth"},{"key":"R21-20230827","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12871-019-0734-6","article-title":"The effect of magnesium on the reversal of rocuronium-induced neuromuscular block with sugammadex: an ex vivo laboratory study","volume":"19","author":"F\u00e1bi\u00e1n","year":"2019","journal-title":"BMC Anesthesiol"},{"key":"R22-20230827","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1213\/ANE.0000000000001197","article-title":"Low-dose or high- dose rocuronium reversed with neostigmine or sugammadex for cesarean delivery anesthesia: a randomized controlled non inferiority trial of time to tracheal intubation and extubation","volume":"122","author":"Stourac","year":"2016","journal-title":"Anesth Analg"},{"key":"R23-20230827","article-title":"Sugammadex administration in pregnant women and in women of reproductive potential: a narrative review","author":"Richardson","year":"2019","journal-title":"Anesth Analg"},{"key":"R24-20230827","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40265-016-0604-1","article-title":"Sugammadex: a review of neuromuscular blockade reversal","volume":"76","author":"Keating","year":"2016","journal-title":"Drugs"},{"key":"R25-20230827","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.bja.2018.05.057","article-title":"Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy nonanaesthetised volunteers","volume":"121","author":"de Kam","year":"2018","journal-title":"Br J Anaesth"},{"key":"R26-20230827","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.bja.2018.05.056","article-title":"Hypersensitivity incidence after sugammadex administration in healthy subjects: a randomised controlled trial","volume":"121","author":"Min","year":"2018","journal-title":"Br J Anaesth"},{"key":"R27-20230827","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.bja.2018.07.014","article-title":"Sugammadex: the sting in the tail?","volume":"121","author":"Savic","year":"2018","journal-title":"Br J Anaesth"},{"key":"R28-20230827","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14740338.2019.1649393","article-title":"Safety of sugammadex for reversal of neuromuscular block","volume":"18","author":"Honing","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"R29-20230827","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1213\/ANE.0000000000004207","article-title":"A retrospective analysis of the safety and efficacy of sugammadex versus neostigmine for the reversal of neuromuscular blockade in children","volume":"129","author":"Gaver","year":"2019","journal-title":"Anesth Analg"},{"key":"R30-20230827","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/anae.13816","article-title":"Sugammadex and laryngospasm","volume":"72","author":"Greenaway","year":"2017","journal-title":"Anaesthesia"},{"key":"R31-20230827","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/anae.13585","article-title":"Did sugammadex cause, or reveal, laryngospasm?","volume":"71","author":"Chrimes","year":"2016","journal-title":"Anaesthesia"},{"key":"R32-20230827","doi-asserted-by":"crossref","first-page":"2042098619869077","DOI":"10.1177\/2042098619869077","article-title":"Risk of bronchospasm and coronary arteriospasm with sugammadex use: a post marketing analysis","volume":"10","author":"Aggarwal","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"R33-20230827","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/bja\/aeq167","article-title":"Repeat dosing of rocuronium 1.2\u200amg kg-1 after reversal of neuromuscular block by sugammadex 4.0\u200amg kg-1 in anaesthetized healthy volunteers: a modelling-based pilot study","volume":"105","author":"Cammu","year":"2010","journal-title":"Br J Anaesth"},{"key":"R34-20230827","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s00540-016-2159-4","article-title":"A case series of re-establishment of neuromuscular block with rocuronium after sugammadex reversal","volume":"30","author":"Iwasaki","year":"2016","journal-title":"J Anesth"},{"key":"R35-20230827","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4097\/kjae.2014.67.1.1","article-title":"Repeat dosing of rocuronium-sugammadex: unpredictable","volume":"67","author":"Kim","year":"2014","journal-title":"Korean J Anesthesiol"},{"key":"R36-20230827","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/BF03016324","article-title":"Nonsteroidal neuromuscular blocking agents to re-establish paralysis after reversal of rocuronium-induced neuromuscular block with sugammadex","volume":"55","author":"de Boer","year":"2008","journal-title":"Can J Anaesth"},{"key":"R37-20230827","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12630-011-9499-1","article-title":"Re-establishment of neuromuscular block by rocuronium after sugammadex administration","volume":"58","author":"Fabregat-Lopez","year":"2011","journal-title":"Can J Anesth"},{"key":"R38-20230827","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12871-019-0887-3","article-title":"Use of sugammadex in patients with neuromuscular disorders: a systematic review of case reports","volume":"19","author":"Gurunathan","year":"2019","journal-title":"BMC Anesthesiol"},{"key":"R39-20230827","article-title":"Effect of sugammadex on postoperative myasthenic crisis in myasthenia gravis patients: propensity score. Analysis of a Japanese Nationwide Database","volume":"2019","author":"Mouri","journal-title":"Anesth Analg"},{"key":"R40-20230827","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jclinane.2019.02.026","article-title":"Sugammadex and postoperative myasthenic crisis","volume":"57","author":"Lai","year":"2019","journal-title":"J Clin Anesth"},{"key":"R41-20230827","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12871-019-0829-0","article-title":"Failure of reversion of neuromuscular block with sugammadex in patient with myasthenia gravis: case report and brief review of literature","volume":"19","author":"dos Santos Fernandes","year":"2019","journal-title":"BMC Anesthesiol"},{"key":"R42-20230827","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/ALN.0b013e31818a3fee","article-title":"Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine","volume":"109","author":"Jones","year":"2008","journal-title":"Anesthesiology"},{"key":"R43-20230827","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jclinane.2017.03.004","article-title":"Role of sugammadex in accelerating postoperative discharge: a meta-analysis","volume":"39","author":"Carron","year":"2017","journal-title":"J Clin Anesth"},{"key":"R44-20230827","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/ALN.0000000000001410","article-title":"Innovative disruption in the world of neuromuscular blockade: what is the \u2018state of the art?\u2019","volume":"126","author":"Naguib","year":"2017","journal-title":"Anesthesiology"},{"key":"R45-20230827","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1213\/ANE.0000000000003589","article-title":"US Food and Drug Administration disruption of generic drug market increases hospital costs","volume":"127","author":"Almeter","year":"2018","journal-title":"Anesth Analg"},{"key":"R46-20230827","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.bja.2018.11.028","article-title":"Retrospective analysis of 30-day unplanned readmission after major abdominal surgery with reversal by sugammadex or neostigmine","volume":"122","author":"Oh","year":"2019","journal-title":"Br J Anaesth"},{"key":"R47-20230827","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/ALN.0b013e31819dabb0","article-title":"Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium. a comparison with spontaneous recovery from succinylcholine","volume":"110","author":"Lee","year":"2009","journal-title":"Anesthesiology"},{"key":"R48-20230827","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/pan.13050","article-title":"Current evidence for the use of sugammadex in children","volume":"27","author":"Tobias","year":"2017","journal-title":"Pediatr Anesth"},{"key":"R49-20230827","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/ALN.0b013e318194caaa","article-title":"Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients","volume":"110","author":"Plaud","year":"2009","journal-title":"Anesthesiology"},{"key":"R50-20230827","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1038\/s41598-017-06159-2","article-title":"The efficacy and safety of sugammadex for reversing postoperative residual neuromuscular blockade in pediatric patients: a systematic review","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"issue":"(Suppl 52)","key":"R51-20230827","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00003643-201406001-00459","article-title":"Reversal of rocuronium-induced neuromuscular block by sugammadex in neonates","volume":"31","author":"Alonso","year":"2014","journal-title":"Eur J Anaesthesiol"},{"key":"R52-20230827","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.accpm.2019.02.010","article-title":"Sugammadex for reversal of neuromuscular blockade in paediatric patients: a two-year single-centre retrospective study","volume":"38","author":"Simonini","year":"2019","journal-title":"Anaesth Crit Care Pain Med"},{"key":"R53-20230827","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1248\/bpb.b19-00044","article-title":"Reversibility of rocuronium-induced deep neuromuscular block with sugammadex in infants and children\u2014a randomized study","volume":"42","author":"Matsui","year":"2019","journal-title":"Biol Pharm Bull"},{"key":"R54-20230827","doi-asserted-by":"crossref","first-page":"e4678","DOI":"10.1097\/MD.0000000000004678","article-title":"Sugammadex for reversal of rocuronium-induced neuromuscular blockade in pediatric patients: a systematic review and meta-analysis","volume":"95","author":"Won","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R55-20230827","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/pan.13401","article-title":"Association between sugammadex and anaphylaxis in pediatric patients: a nested case-control study using a national inpatient database","volume":"28","author":"Tadokoro","year":"2018","journal-title":"Paediatr Anaesth"},{"key":"R57-20230827","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.aan.2011.07.007","article-title":"Sugammadex: past, present, and future","volume":"29","author":"Caldwell","year":"2011","journal-title":"Adv Anesth"},{"key":"R58-20230827","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2344\/anpr-66-01-07","article-title":"Two cases of rocuronium-induced anaphylaxis\/anaphylactic shock successfully treated with sugammadex","volume":"66","author":"Hashimoto","year":"2019","journal-title":"Anesth Progress"},{"key":"R59-20230827","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/bja\/aeq366","article-title":"Sugammadex in the management of rocuronium-induced anaphylaxis","volume":"106","author":"McDonnell","year":"2011","journal-title":"Br J Anaesth"},{"key":"R60-20230827","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/bja\/aer211","article-title":"A further case of rocuronium-induced anaphylaxis treated with sugammadex","volume":"107","author":"Funnell","year":"2011","journal-title":"Br J Anaesth"},{"key":"R61-20230827","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3724\/SP.J.1008.2015.00507","article-title":"Spectroscopy study on the interaction of \u03b3-cyclodextrin and its two derivatives with rocuronium and vecuronium","volume":"36","author":"Chen","year":"2015","journal-title":"Acad J Second Mil Med Uni"},{"key":"R62-20230827","first-page":"515","article-title":"Screened adamgammadex for reversing rocuronium-induced neuromuscular blockade with greater safety","volume":"32","author":"Qi","year":"2018","journal-title":"Chin J Pharmacol Toxicol"},{"key":"R63-20230827","doi-asserted-by":"crossref","first-page":"105134","DOI":"10.1016\/j.ejps.2019.105134","article-title":"Safety, tolerability, and pharmacokinetics of adamgammadex sodium, a novel agent to reverse the action of rocuronium and vecuronium, in healthy volunteers","volume":"141","author":"Jiang","year":"2020","journal-title":"Eur J Pharm Sci"}],"container-title":["Current Opinion in Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000000847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:13:14Z","timestamp":1693095194000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000000847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/aco.0000000000000847","relation":{},"ISSN":["0952-7907","1473-6500"],"issn-type":[{"value":"0952-7907","type":"print"},{"value":"1473-6500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}